HDA’s Kala Shankle is addressing one of the most pressing open questions in pharmaceutical distribution: what national licensure will mean for wholesalers and third-party logistics providers.
Shankle, speaking to the biggest unresolved issue around preemption, has laid out a clear two-step approach for industry players preparing for the regulatory shift.
The move toward national licensure represents a significant structural change for wholesalers and 3PLs operating across multiple state jurisdictions in the United States.
Currently, pharmaceutical distributors must navigate a patchwork of state-level licensing requirements, creating administrative complexity and compliance costs across the supply chain.
National licensure, if implemented, would replace or supersede many of those state-level frameworks, raising fundamental questions about how federal rules interact with existing state authority.
Preemption sits at the heart of that debate, determining the extent to which a national licensing regime would override state regulations that wholesalers and 3PLs currently operate under.
Shankle’s two-step playbook is designed to give distribution companies a practical framework for getting ahead of the changes before final regulatory guidance is in place.
Industry groups and supply chain operators have been closely watching legislative and regulatory developments, recognising that national licensure could reshape compliance obligations significantly.
For 3PLs in particular, the implications could be substantial, given their role in handling, storing, and distributing pharmaceutical products on behalf of manufacturers and wholesalers.
Preparation now, rather than waiting for full regulatory clarity, is emerging as the dominant strategy among supply chain leaders who want to avoid being caught flat-footed by implementation timelines.
The Healthcare Distribution Alliance has positioned itself as a key voice in shaping how national licensure policy develops and how the industry responds to it.
Shankle’s commentary reflects the broader effort by HDA to equip its members with actionable guidance during what remains a period of considerable regulatory uncertainty.